Efavirenz dose reduction is safe in patients with high plasma concentrations and may prevent efavirenz discontinuations

Journal of Acquired Immune Deficiency Syndromes

Volumn 52, Issue 2, 2009, Pages 240-245

  Van Luin, Matthijs ^a,b   Gras, Luuk ^c   Richter, Clemens ^b   Van Der Ende, Marchina E ^d   Prins, Jan M ^e   Wolf, Frank De ^c,f   Burger, David M ^a   Wit, Ferdinand W ^e  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RIJNSTATE HOSPITAL   (Netherlands)

^c STICHTING HIV MONITORING   (Netherlands)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e ACADEMIC MEDICAL CENTER   (Netherlands)

^f IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Dose reduction; Efavirenz; Therapeutic drug monitoring; Toxicity

Indexed keywords

EFAVIRENZ; EMTRICITABINE; LAMIVUDINE; TENOFOVIR DISOPROXIL; ZIDOVUDINE;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; UNSPECIFIED SIDE EFFECT;

ADULT; ANTI-HIV AGENTS; BENZOXAZINES; DRUG MONITORING; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; MODELS, STATISTICAL; NETHERLANDS; PLASMA; VIRAL LOAD;

EID: 70349656909     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181b061e6     Document Type: Article

References (18)

1. Burger D, Hugen P, Reiss P, et al, for the ATHENA Cohort Study Group. Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individuals. AIDS. 2003;17:1157-1165.
2. Fletcher CV, Anderson PL, Kakuda TN, et al. Concentration-controlled compared with conventional antiretroviral therapy for HIV infection. AIDS. 2002;16:551-560.
3. Best BM, Goicoechea M,Witt MD, et al. A randomized controlled trial of therapeutic drug monitoring in treatment-naive and -experienced HIV-1- Infected Patients. J Acquir Immune Defic Syndr. 2007;46:433-442.
4. Marzolini C, Telenti A, Decosterd LA, et al. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1- infected patients. AIDS. 2001;15:71-75. (Pubitemid 32055781)
5. Burger D, Van der Heiden I, laPorte C, et al. Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism. Br J Clin Pharmacol. 2006;61:148-154.
6. Khoo SH, Lloyd J, Dalton M, et al. Pharmacologic optimization of protease inhibitors and nonnucleoside reverse transcriptase inhibitors (POPIN)-a randomized controlled trial of therapeutic drug monitoring and adherence support. J Acquir Immune Defic Syndr. 2006;41:461-467.
7. Staszewski S, Morales-Ramirez J, Tashima KT, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med. 1999;341:1865-1873.
8. Gutierrez F, Navarro A, Padilla S, et al. Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring. Clin Infect Dis. 2005;41:1648-1653.
9. Nunez M, Gonzalez dR, Gallego L, et al. Higher efavirenz plasma levels correlate with development of insomnia. J Acquir Immune Defic Syndr. 2001;28:399-400.
10. Gallego L, Barreiro P, del Rio R, et al. Analyzing sleep abnormalities in HIV-infected patients treated with Efavirenz. Clin Infect Dis. 2004;38: 430-432.
11. Haas DW, Ribaudo HJ, Kim RB, et al. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS. 2004;18:2391-2400.
12. La Porte CJ, Back DJ, Blaschke T, et al. Updated guideline to perform therapeutic drug monitoring for antiretroviral agents. Rev Antivir Ther. 2006;3:4-14.
13. Gras L, van Sighem AI, Smit C, et al. Monitoring of Human Immunodeficiency Virus (HIV) Infection in The Netherlands. Report 2008. Available at: http://www.hiv-monitoring.nl.
14. Stohr W, Back D, Dunn D, et al. Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and comedication. Antivir Ther. 2008;13:675-685.
15. Pfister M, Labbe L, Hammer SM, et al. Population pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavir: Adult AIDS Clinical Trial Group Study 398. Antimicrob Agents Chemother. 2003;47: 130-137.
16. Ward BA, Gorski JC, Jones DR, et al. The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther. 2003;306:287-300.
17. Rotger M, Tegude H, Colombo S, et al. Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals. Clin Pharmacol Ther. 2007;81:557-566.
18. Wyen C, Hendra H, Vogel M, et al. Impact of CYP2B6 983T.C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients. J Antimicrob Chemother. 2008; 61:914-918.